ASCO 2018 | MM trial highlights from ASCO 2018
Vincent Rajkumar, MD, of the Mayo Clinic, Rochester, MN, gives an overview of his top 5 abstract presentations at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. These include: the CRB-401 study (NCT02658929) showing positive results for anti-BCMA CAR T-cell agent bb2121; ARROW (NCT02412878), which showed that once-weekly carfilzomib was as effective and well-tolerated as a twice-weekly dosage; COLUMBA (NCT03277105), which demonstrated subcutaneous daratumumab was safe and effective; OPTIMISMM (NCT01734928), which showed that a triplet therapy of pomalidomide, bortezomib and dexamethasone was well tolerated and more effective than bortezomib/dexamethasone alone; and SWOG-S1304 (NCT01903811), which showed no significant PFS or OS difference between low- and high-dose carfilzomib.
